Global
Non-melanoma Skin Cancer Market 2014-2018 is the latest addition
to Sandlerresearch.org industry research reports collection.
Non-melanoma skin
cancer is one of the most common types of cancer in the world. It develops in
the upper layers of the skin, but not in melanocytes. There are two types of
non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which
starts in the squamous cells. BCC usually develops in the areas such as the
head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of
the hands. These can also grow in wounds or chronic skin sores. Non-melanoma
skin cancer is caused by unprotected and excessive exposure to UV radiation. It
affects men more than women. It can be cured effectively if it is detected
early. Treatment for non-melanoma skin cancer includes surgery, laser therapy,
cryotherapy, creams, radiotherapy, chemotherapy, and PDT.Analysts forecast the
Global Non-melanoma Skin
Cancer
market to grow at a CAGR of 27.93 percent over the period 2013-2018.
Covered in this
Report
This report
covers the present scenario and the growth prospects of the Global Non-melanoma
Skin Cancer market for the period 2014-2018. To calculate the market size, the
report considers the revenue generated from the following segments:
Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and
actinic keratosis Non-invasive Treatments, which include PDT, radiotherapy,
cryotherapy, and laser therapy
Global
Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report covers
the Americas and, the EMEA and the APAC region; and its growth prospects in the
coming years. The report also includes a discussion of the key vendors
operating in this market.
Key Vendors
- Elekta AB
- F. Hoffmann-la Roche Ltd.
- iCAD Inc.
- Meda AB
- Valeant Pharmaceuticals Inc.
- Varian Medical Systems Inc.
